Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation

Liver Transplantation

Volumn 13, Issue 9, 2007, Pages 1236-1245

  Charatcharoenwitthaya, Phunchai ^a   Pimentel, Sylvania ^a   Talwalkar, Jayant A ^a   Enders, Felicity T ^a   Lindor, Keith D ^a   Krom, Ruud A F ^a   Wiesner, Russell H ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS; URSODEOXYCHOLIC ACID;

ADULT; AGE DETERMINATION; AGED; ARTICLE; BRAIN HEMORRHAGE; CARDIOGENIC SHOCK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PERFORATION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR; SEPSIS; SEX DIFFERENCE; SURVIVAL TIME; TREATMENT DURATION;

ADULT; AGED; CHOLAGOGUES AND CHOLERETICS; FEMALE; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROBABILITY; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVORS; URSODEOXYCHOLIC ACID;

EID: 34648843072     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21124     Document Type: Article

References (42)

1. Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet 2003;362:53-61.
2. Sebagh M, Farges O, Dubel L, Samuel D, Bismuth H, Reynes M. Histological features predictive of recurrence of primary biliary cirrhosis after liver transplantation. Transplantation 1998;65:1328-1333.
3. Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001;33:22-27.
4. Sylvestre PB, Batts KP, Burgart LJ, Poterucha JJ, Wiesner RH. Recurrence of primary biliary cirrhosis after liver transplantation: histologic estimate of incidence and natural history. Liver Transpl 2003;9:1086-1093.
5. Abu-Elamgd K, Demetris J, Rakela J, Balan V, Vinayek R, Irish W, et al. Transplantation for primary biliary cirrhosis: recurrence and outcome in 421 patients [Abstract]. Hepatology 1997;26:176A.
6. Hubscher S, Elias E, Buckels J, Mayer AD, McMaster P, Neuberger JM. Primary biliary cirrhosis. Histological evidence of disease recurrence after liver transplantation. J Hepatol 1993:18:173-184.
7. Hashimoto E, Shimada M, Noguchi S, Taniai M, Tokushige K, Hayashi N, et al. Disease recurrence after living liver transplantation for primary biliary cirrhosis: a clinical and histological follow-up study. Liver Transpl 2001;7:588-595.
8. Polson RJ, Portmann B, Neuberger J, Calne RY, Williams R. Evidence for disease recurrence after liver transplantation for primary biliary cirrhosis. Clinical and histologic follow-up studies. Gastroenterology 1989;97:715-725.
9. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000;31:1005-1013.
10. Poupon RE, Balkau B, Eschwege E, Poupon R, UDCA-PBC Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991;324:1548-1554.
11. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994;106:1284-1290.
12. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994;19: 1149-1156.
13. Combes B, Carithers RL Jr, Maddrey WC, Lin D, McDonald MF, Wheeler DE, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995;22:759-766.
14. Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999;29:644-647.
15. Poupon RE, Lindor KD, Pares A, Chazouilleres O, Poupon R, Heathcote EJ. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003;39:12-16.
16. Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000;32:1196-1199.
17. Pares A, Caballeria L, Rodes J, Bruguera M, Rodrigo L, Garcia-Plaza A, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. J Hepatol 2000;32:561-566.
18. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-890.
19. Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005;128:297-303.
20. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33: 464-470.
21. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989;10:1-7.
22. Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation. N Engl J Med. 1989;321:1014-1022.
23. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978;379:103-112.
24. Knoop M, Bechstein WO, Schrem H, Lobeck H, Hopf U, Neuhaus P. Clinical significance of recurrent primary biliary cirrhosis after liver transplantation. Transpl Int 1996; 9(Suppl 1):S115-S119.
25. Levitsky J, Hart J, Cohen SM, Te HS. The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation. Liver Transpl 2003;9:733-736.
26. Salguero O, Moreno JM, Seijas MC, Rubio E, Salas C, Laporta R, et al. Recurrence of primary biliary cirrhosis after liver transplantation. Transplant Proc 2003;35:721-722.
27. Sanchez EQ, Levy MF, Goldstein RM, Fasola CG, Tillery GW, Netto GJ, et al. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. Transplantation 2003;76:1583-1588.
28. Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2004;10:488-491.
29. Guy JE, Qian P, Lowell JA, Peters MG. Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant. Liver Transpl 2005;11:1252-1257.
30. Jacob DA, Neumann UP, Bahra M, Klupp J, Puhl G, Neuhaus R, et al. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin Transplant 2006;20:211-220.
31. Charatcharoenwitthaya P, Lindor KD. Current concepts in the pathogenesis of primary biliary cirrhosis. Ann Hepatol 2005;4:161-175.
32. Haagsma EB. Clinical relevance of recurrence of primary biliary cirrhosis after liver transplantation. Eur J Gastroenterol Hepatol 1999;11:639-642.
33. Lunz JG 3rd, Contrucci S, Ruppert K, Murase N, Fung JJ, Starzl TE, et al. Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21 (WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs. Am J Pathol 2001;158:1379-1390.
34. Vierling JM. Future treatment options in PBC. Semin Liver Dis 2005;25:347-363.
35. Rubel LR, Rabin L, Seeff LB, Licht H, Cuccherini BA. Does primary biliary cirrhosis in men differ from primary biliary cirrhosis in women? Hepatology 1984;4:671-677.
36. Madersbacher S, Ludvik G, Stulnig T, Grunberger T, Maier U. The impact of liver transplantation on endocrine status in men. Clin Endocrinol (Oxf) 1996;44:461-466.
37. Kantarci G, Sahin S, Uras AR, Ergin H. Effects of different calcineurin inhibitors on sex hormone levels in transplanted male patients. Transplant Proc 2004;36:178-179.
38. Jacob DA, Neumann UP, Bahra M, Langrehr JM, Neuhaus P. Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival. Transplant Proc 2005;37:1691-1692.
39. Stegall MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation 1997;64:1755-1760.
40. Gomez R, Moreno E, Colina F, Loinaz C, Gonzalez-Pinto I, Lumbreras C, et al. Steroid withdrawal is safe and beneficial in stable cyclosporine-treated liver transplant patients. J Hepatol 1998;28:150-156.
41. Charlton M. The impact of advancing donor age on histologic recurrence of hepatitis C infection: the perils of ignored maternal advice. Liver Transpl 2003;9:535-537.
42. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006;130:715-720.